FrancophonIA/ELRC3.0 huggingface dataset:
English: • Weight loss
Croatian: • Gubitak tjelesne težine
English: • Guide for healthcare professionals
Croatian: • Vodič za zdravstvene radnike
English: Each 4 mL dose contains approximately 30 mg (1.3 mmol) sodium and 80 mg sorbitol.
Croatian: Svaka doza od 4 ml sadrži približno 30 mg (1,3 mmol) natrija i 80 mg sorbitola.
English: Healthcare professionals and close contacts (e.g. household members, caregivers, sex partners or persons sharing the same bed) should avoid direct contact with injected lesions or body fluids of treated patients during the entirety of the treatment period and up to 30 days after the last treatment administration (see section 6.6).
Croatian: Zdravstveni radnici i osobe u neposrednoj blizini ( npr. članovi kućanstva, njegovatelji, seksualni partneri ili osobe koje dijele isti krevet) trebaju izbjegavati izravan doticaj s injiciranim lezijama ili tjelesnim tekućinama liječenih bolesnika tijekom cijelog perioda liječenja i do 30 dana nakon posljednje primjene lijeka (vidjeti dio 6.6).
English: The MAH shall ensure that in each Member State where IMLYGIC is marketed, all healthcare professionals and patients/carers who are expected to prescribe, dispense and use IMLYGIC have access to/are provided with the following educational package:
Croatian: Nositelj odobrenja će osigurati da u svim zemljama članicama gdje je lijek IMLYGIC stavljen u promet, svi zdravstveni radnici i bolesnici/njegovatelji za koje se očekuje da će propisivati, izdavati i primjenjivati lijek IMLYGIC, imaju pristup/dobiju sljedeće edukacijske materijale:
English: • Place all used dressings and cleaning materials in a sealed plastic bag and throw them away in your household waste.
Croatian: • Sve iskorištene zavoje i materijale za čišćenje stavite u zapečaćenu plastičnu vrećicu i bacite ih u Vaš kućni otpad.
English: Store in the original carton in order to protect from light.
Croatian: Čuvati u originalnoj kutiji radi zaštite od svjetlosti.
English: Your healthcare professional will decide which tumour(s) to inject and may not inject every tumour.
Croatian: Vaš zdravstveni radnik će odlučiti u koji/e tumor/e će injicirati lijek te možda neće injicirati u svaki tumor.
English: Imlygic is given in a healthcare facility under the supervision of a healthcare professional.
Croatian: Imlygic se primjenjuje u zdravstvenoj ustanovi pod nadzorom zdravstvenog radnika.
English: If you have a tumour in your neck, your healthcare professional may warn you that you might experience compression of your airways during treatment with Imlygic.
Croatian: Ako imate tumor u vratu, Vaš zdravstveni radnik Vas može upozoriti da može doći do sužavanja Vaših dišnih puteva tijekom liječenja lijekom Imlygic.
English: Caregivers should be advised to wear protective gloves when assisting patients in applying or changing occlusive dressings and to observe safety precautions for disposal of used dressings and cleaning materials (see sections 4.2 and 6.6).
Croatian: Njegovatelje treba savjetovati da nose zaštitne rukavice dok pomažu bolesnicima u nanošenju ili mijenjanju okluzivnih zavoja te da se pridržavaju sigurnosnih mjera pri odlaganju iskorištenih zavoja i materijala za čišćenje (vidjeti dijelove 4.2 i 6.6).
English: GM-CSF was administered subcutaneously at 125 µg/m2 delivered daily for 14 days followed by a 14-day rest period in repeating intervals.
Croatian: GM-CSF je primijenjen supkutano u dozi od 125 µg/m2 dnevno kroz 14 dana uz naknadni period prekida od 14 dana, u ponavljajućim intervalima.
English: Patients with no prior herpes infection
Croatian: Bolesnici bez prethodnih infekcija herpes virusom
English: Of the enrolled patients, 22% had stage IV M1c disease and 53% of patients had received prior therapy for melanoma such as chemotherapy and cytokine-based immunotherapy in addition to surgery, adjuvant therapy or radiation.
Croatian: Od uključenih bolesnika, 22% je imalo stadij IV M1c bolesti, a u 53% bolesnika je prethodno već primijenjeno liječenje melanoma poput kemoterapije i citokinske imunoterapije dodatno uz operaciju, adjuvantno liječenje ili zračenje.
English: • Avoid touching or scratching the injection sites.
Croatian: • Izbjegavajte diranje ili grebanje mjesta injiciranja.
English: If the qPCR testing for talimogene laherparepvec DNA was positive, then a TCID50 assay was performed to measure viral infectivity.
Croatian: Ako je qPCR testiranje za DNK virusa talimogene laherparepvec bilo pozitivno, tada je proveden TCID50 test za mjerenje infektivnosti virusa.
English: • Using a single insertion point, inject Imlygic along multiple tracks as far as the radial reach of the needle allows within the lesion to achieve even and complete dispersion.
Croatian: • Koristeći jedno mjesto injiciranja, injicirajte Imlygic uzduž više putanja, dokle god to radijalni doseg igle omogućuje unutar lezije, kako bi se postigla ravnomjerna i potpuna raspodjela.
English: 90% of patients treated with Imlygic experienced influenza-like symptoms.
Croatian: U 90% bolesnika liječenih lijekom Imlygic došlo je do simptoma nalik gripi.
English: Up to 4 mL
Croatian: Do 4 ml
English: The secondary endpoints included overall survival (OS), overall response rate (ORR) [PR+CR], time to response, duration of response, and time to treatment failure (time from randomisation until the first episode of clinically relevant disease progression where there is no response achieved after the progression event, or until death).
Croatian: Sekundarni ishodi uključivali su ukupno preživljenje (OS, od engl. overall survival), učestalost sveukupnog odgovora (ORR, od engl. overall response rate) [PR+CR], vrijeme do odgovora, trajanje odgovora i vrijeme do neuspjeha liječenja (vrijeme od randomizacije do prvog događaja klinički relevantne progresije bolesti gdje nije postignut odgovor nakon događaja progresije ili do smrti).
English: Median 2.8 months (Range: 1.2 to > 14.9 months)
Croatian: Medijan 2,8 mjeseci (Raspon: 1,2 do > 14,9 mjeseci)
English: Do not exceed the storage times specified in table 7 and table 8.
Croatian: Nemojte prekoračiti vrijeme čuvanja navedeno u tablici 7 i tablici 8.
English: • Patients with a weakened immune system (immunocompromised patients) treated with IMLYGIC and suffering from concomitant infection
Croatian: • Bolesnici s oslabljenim imunološkim sustavom (imunokompromitirani bolesnici) liječeni lijekom IMLYGIC koji pate od istodobne infekcije
English: • Symptomatic herpetic infection due to latency and reactivation of IMLYGIC or herpes (wildtype HSV-1) in patients
Croatian: • Simptomatska infekcija herpes virusom radi latencije i reaktivacije lijeka IMLYGIC ili herpes virusa (divlji tip HSV-1) u bolesnika
English: If you are pregnant or breast-feeding, ask your healthcare professional for advice before being given this medicine.
Croatian: Ako ste trudni ili dojite, obratite se svom zdravstvenom radniku za savjet prije nego
English: Sixty patients with melanoma received Imlygic intralesional injection at a dose and schedule same as clinical study 005/05 (see section 5.1).
Croatian: Šezdeset bolesnika s melanomom primilo je lijek Imlygic intralezijskom injekcijom u istoj dozi i po istom rasporedu kao i u kliničkom ispitivanju 005/05 (vidjeti dio 5.1).
English: The volume of Imlygic to be injected into each lesion is dependent on the size of the lesion and should be determined according to table 2.
Croatian: Volumen lijeka Imlygic koji će se injicirati u svaku leziju ovisi o veličini lezije i treba ga odrediti prema Tablici 2.
English: During this period, treatment was to continue despite an increase in size in existing lesion(s) and/or development of new lesion(s) unless the patient developed intolerable toxicity or the investigator believed that it was in the best interest of the patient to stop treatment or to be given other therapy for melanoma.
Croatian: Tijekom tog razdoblja, liječenje je trebalo nastaviti bez obzira na povećanje veličine postojeće/ih lezije/a i/ili razvoj nove/ih lezije/a, osim ako se u bolesnika razvila nepodnošljiva toksičnost ili ako je ispitivač smatrao da je u najboljem interesu bolesnika prekinuti liječenje ili primijeniti drugu terapiju za melanom.
English: It is recommended to keep injection sites covered with airtight and watertight dressings at all times, if possible.
Croatian: Preporučeno je mjesta injiciranja držati pokrivenima zavojem nepropusnim za zrak i vodu cijelo vrijeme, ako je moguće.
English: Overall survival
Croatian: Sveukupno preživljenje
English: To provide preliminary efficacy results from the phase III part of the Study 20110265 (a multicentre trial evaluating the combination of talimogene laherparepvec with pembrolizumab)
Croatian: Pružiti preliminarne rezultate o djelotvornosti iz dijela faze III ispitivanja 20110265 (multicentrično ispitivanje za procjenu kombinacije virusa talimogene laherparepvec s pembrolizumabom)
English: Ensure that your close contacts who are pregnant or who have a weakened immune system do not touch injection sites, used dressings and cleaning materials.
Croatian: Pobrinite se da osobe u Vašoj neposrednoj blizini koji su trudnice ili imaju oslabljen imunološki sustav ne dodiruju mjesta injiciranja, iskorištene zavoje i materijale za čišćenje.
English: • Avoid direct contact with your body fluids or injection sites.
Croatian: • Izbjegavaju izravan kontakt s Vašim tjelesnim tekućinama ili mjestima injiciranja.
English: Healthcare professionals should ensure that patients are able to comply with the requirement to cover injection sites with occlusive dressings (see section 6.6).
Croatian: Zdravstveni djelatnici trebaju se pobrinuti da bolesnici mogu ispuniti zahtjev da se mjesta injiciranja prekriju okluzivnim zavojem (vidjeti dio 6.6).
English: • The injection site may be treated with a topical anaesthetic agent.
Croatian: • Mjesto injiciranja može se tretirati topikalnim anestetikom.
English: The most commonly reported adverse reactions (≥ 25%) in Imlygic-treated patients were fatigue (50.3%), chills (48.6%), pyrexia (42.8%), nausea (35.6%), influenza-like illness (30.5%), and injection site pain (27.7%).
Croatian: Najčešće prijavljene nuspojave (≥ 25%) u bolesnika liječenih lijekom Imlygic su bile umor (50,3%), zimica (48,6%), pireksija (42,8%), mučnina (35,6%), bolest nalik gripi (30,5%) i bol na mjestu injiciranja (27,7%).
English: In an analysis to evaluate systemic activity of Imlygic, 27 of 79 patients (34.2%) had a ≥ 50% overall decrease in non-visceral lesions that were not injected with Imlygic, and 8 of 71 patients (11.3%) had a ≥ 50% overall decrease in visceral lesions that were not injected with Imlygic.
Croatian: U analizi za procjenu sustavne aktivnosti lijeka Imlygic, u 27 od 79 bolesnika (34,2%) došlo je do sveukupnog smanjenja od ≥ 50% za ne-visceralne lezije u koje nije injiciran lijek Imlygic, dok je u 8 od 71 bolesnika (11,3%) došlo do sveukupnog smanjenja od ≥ 50% za visceralne lezije u koje nije injiciran lijek Imlygic.
English: Talk to your healthcare professional before being given Imlygic.
Croatian: Obratite se svom zdravstvenom radniku prije primjene lijeka Imlygic.
English: OS (hazard ratio) Imlygic GM-CSF Imlygic GM-CSF Imlygic vs GM-CSF
Croatian: OS (omjer rizika) Imlygic GM-CSF Imlygic GM-CSF Imlygic naprema GM-CSF
English: Imlygic may cause infection at the injection site.
Croatian: Imlygic može uzrokovati infekciju na mjestu injiciranja.
English: Dose concentrations
Croatian: Koncentracije doze
English: • Tissue swelling (peripheral oedema)
Croatian: • Oticanje tkiva (periferni edem)
English: Kaplan-Meier plot -overall survival (ITT population)
Croatian: Slika 4. Kaplan-Meierova krivulja sveukupnog preživljenja (ITT populacija)
English: • Cancerous white blood cells at or near the injection site (plasmacytoma).
Croatian: • Tumorske bijele krvne stanice na mjestu ili blizu mjesta injiciranja (plazmocitom).
English: Patients treated with Imlygic must be given the patient alert card and be informed about the risks of Imlygic (see also package leaflet).
Croatian: Bolesnicima koji se liječe lijekom Imlygic mora se dati Kartica s upozorenjima za bolesnika i mora ih se informirati o rizicima primjene lijeka Imlygic (također vidjeti Uputu o lijeku).
English: Overall 3 of 19 patients with lesions of suspected herpetic origin had talimogene laherparepvec DNA present at any time during the study.
Croatian: Ukupno 3 od 19 bolesnika s lezijama sumnjivog herpetičkog porijekla imalo je DNK virusa talimogene laherparepvec prisutnu u svakom trenutku tijekom ispitivanja.
English: Talimogene laherparepvec has been modified to replicate within tumours and to produce the immune stimulatory protein human GM-CSF.
Croatian: Virus talimogene laherparepvec modificiran je tako da se replicira unutar tumora i proizvodi imunostimulator, humani protein GM-CSF.
English: • Advise patients to place used dressings and cleaning materials in a sealed plastic bag as they may be potentially contaminated, and to dispose of the bag in household waste.
Croatian: • Savjetujte bolesnike da odlažu iskorištene zavoje i materijale za čišćenje u zapečaćenu plastičnu vrećicu jer oni mogu biti kontaminirani, te da vrećicu bace u kućni otpad.
English: Neoplasms benign, malignant and unspecified (including cysts and polyps) Common
Croatian: Dobroćudne, zloćudne i nespecificirane novotvorine (uključujući ciste i polipe) Često
English: Based on animal data, patients who are severely immunocompromised may be at an increased risk of disseminated herpetic infection and should not be treated with Imlygic (see sections 4.3 and 5.3).
Croatian: Na temelju podataka dobivenih na životinjama, bolesnici koji su teško imunokompromitirani mogu biti pod povećanim rizikom od diseminirane infekcije herpes virusom te se ne smiju liječiti lijekom Imlygic (vidjeti dijelove 4.3 i 5.3).
English: • When removing the needle, withdraw it from the lesion slowly to avoid leakage or splash back of Imlygic at the insertion point.
Croatian: • Kada uklanjate iglu, izvucite ju iz lezije polako kako bi se izbjeglo curenje ili štrcanje lijeka Imlygic na mjestu injiciranja.
English: * See description of selected adverse reactions
Croatian: * Pogledajte opis odabranih nuspojava
English: Imlygic will be stored by the healthcare professionals at your healthcare facility.
Croatian: Imlygic će čuvati zdravstveni radnik u Vašoj zdravstvenoj ustanovi.
English: If a pregnant woman has an infection with wild type HSV-1 (primary or reactivation), there is potential for the virus to cross the placental barrier, and also a risk of transmission during birth due to viral shedding.
Croatian: Ako trudnica ima infekciju divljim tipom virusa HSV-1 (primarnu ili reaktivaciju), postoji mogućnost da virus prijeđe placentalnu barijeru te rizik od prijenosa tijekom poroda zbog izlučivanja virusa.
English: Imlygic may increase the risk of impaired healing in patients with underlying risk factors (e.g. previous radiation at the injection site, or lesions in poorly vascularised areas).
Croatian: Imlygic može povećati rizik od otežanog zacjeljivanja u bolesnika s podležećim rizičnim čimbenicima (npr. prijašnje zračenje na mjestu injiciranja ili lezije na slabo prokrvljenim područjima).
English: Acyclovir and other anti-viral treatments may decrease the effects of Imlygic.
Croatian: Aciklovir i drugi antivirusni lijekovi mogu umanjiti učinak lijeka Imlygic.
English: To allow for delayed immune-mediated anti-tumour effects to occur, patients were treated for a minimum of 6 months or until there were no longer any injectable lesions.
Croatian: Kako bi se omogućio odgođeni imunološki posredovan antitumorski učinak, bolesnici su liječeni kroz najmanje 6 mjeseci ili sve dok više nije bilo lezija za injiciranje.
English: If they develop signs or symptoms of herpes infection, you should ask them to contact their healthcare professional.
Croatian: Ako razviju znakove ili simptome infekcije herpes virusom, trebate ih tražiti da kontaktiraju svog zdravstvenog radnika.
English: To minimise the risk of viral transmission, patients should keep their injection site covered for at least 8 days from the last treatment or longer if the injection site is weeping or oozing.
Croatian: Kako bi se rizik od virusnog prijenosa sveo na najmanju moguću mjeru, bolesnici bi trebali držati svoja mjesta injiciranja pokrivena najmanje 8 dana nakon posljednjeg liječenja, ili duže, ako iz mjesta injiciranja kapa ili curi.
English: While there are no clinical data to date on talimogene laherparepvec infections in pregnant women, there could be a risk to the foetus or neonate if talimogene laherparepvec were to act in the same manner.
Croatian: Iako do danas nema kliničkih podataka o infekcijama virusom talimogene laherparepvec u trudnica, mogao bi postojati rizik za fetus ili novorođenče ako bi virus talimogene laherparepvec djelovao na isti način.
English: • Draw the desired amount of Imlygic from the vial into a syringe using aseptic technique.
Croatian: • Uvucite željenu količinu lijeka Imlygic iz bočice u štrcaljku, koristeći aseptičku tehniku.
English: Do not exceed the storage times specified in table 1 and table 2.
Croatian: Nemojte prekoračiti vrijeme čuvanja navedeno u tablici 1 i tablici 2.
English: Talimogene laherparepvec is an attenuated herpes simplex virus type-1 (HSV-1) derived by functional deletion of 2 genes (ICP34.5 and ICP47) and insertion of coding sequence for human granulocyte macrophage colony-stimulating factor (GM-CSF) (see section 5.1).
Croatian: Talimogene laherparepvec je oslabljeni Herpes simplex virus tip 1 (HSV-1) izveden funkcionalnom delecijom 2 gena (ICP34.5 i ICP47) i insercijom kodirajuće sekvence za ljudski faktor stimulacije kolonija granulocita i makrofaga (GM-CSF, od engl. granulocyte macrophage colony-stimulating factor) (vidjeti dio 5.1 ).
English: In clinical trials, one case of plasmacytoma at injection site was observed in a patient who was found to have multiple myeloma.
Croatian: U kliničkim ispitivanjima, opažen je jedan slučaj plazmocitoma na mjestu injiciranja u bolesnika za kojeg se ustanovilo da ima multipli mijelom.
English: The recommended dosing schedule for Imlygic is shown in table 1.
Croatian: Preporučeni raspored doziranja lijeka Imlygic prikazan je u Tablici 1. Tablica 1.
English: Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease (see sections 4.4 and 5.1).
Croatian: Imlygic je indiciran za liječenje odraslih osoba s inoperabilnim melanomom koji je metastazirao regionalno ili distalno (stadij IIIB, IIIC i IVM1a), bez bolesti kostiju, mozga, pluća ili druge visceralne bolesti(vidjeti dijelove 4.4 i 5.1).
English: • In the event of an accidental occupational exposure to Imlygic (e.g. through a splash to the eyes or mucous membranes) during preparation or administration, flush with clean water for at least 15 minutes.
Croatian: • U slučaju slučajne profesionalne izloženosti lijeku Imlygic (npr. putem prskanja u oko ili na površinu sluznice) tijekom pripreme ili primjene, ispirati čistom vodom kroz najmanje 15 minuta.
English: Stage§ IIIB/IIIC/ stage IVM1a (Imlygic, n = 163; GM-CSF, n = 86)
Croatian: Stadij§ IIIB/IIIC/ stadij IVM1a (Imlygic, n = 163; GM-CSF, n = 86)
English: If Imlygic is used during pregnancy, or if the patient becomes pregnant while taking Imlygic, the patient should be apprised of the potential hazards to the foetus and/or neonate.
Croatian: Ako se Imlygic primjenjuje tijekom trudnoće ili bolesnica postane trudna tijekom primjene lijeka Imlygic, bolesnicu treba upoznati s mogućim opasnostima za fetus i/ili novorođenče.
English: Herpes infection
Croatian: Infekcija herpes virusom
English: There is no clinical experience with overdose with Imlygic.
Croatian: Ne postoji kliničko iskustvo o predoziranju lijekom Imlygic.
English: Secondary
Croatian: Sekundarni
English: As long as there are injectable lesion(s) remaining, Imlygic should be continued for at least 6 months unless the physician considers that the patient is not benefitting from Imlygic treatment or that other treatment is required.
Croatian: Sve dok postoje lezije u koje se može injicirati, primjenu lijeka Imlygic treba nastaviti kroz najmanje 6 mjeseci, osim ako liječnik ne smatra da bolesnik nema koristi od liječenja lijekom Imlygic ili da mu je potrebno drugo liječenje.
English: • After thawing, administer Imlygic as soon as practically feasible.
Croatian: • Nakon odmrzavanja, primijenite Imlygic što je prije moguće.
English: Imlygic is provided in single use vials of 1 mL each in two different concentrations:
Croatian: Imlygic je dostupan u bočicama za jednokratnu primjenu od po 1 ml, u dvije različite koncentracije:
English: • Avoid direct contact between your injection sites or body fluids (e.g. blood and urine) and close contacts (e.g. use latex condoms when engaging in sexual activity, avoid kissing close contacts if either of you has an open mouth sore) while you are being treated with Imlygic and up to 30 days after your last dose.
Croatian: • Izbjegavajte izravan kontakt Vaših mjesta injiciranja ili tjelesnih tekućina (npr. krv ili mokraća) s Vašim osobama u neposrednoj blizini (npr. koristite kondom od lateksa prilikom seksualne aktivnosti, izbjegavajte ljubljenje s osobama u neposrednoj blizini ako bilo tko od vas ima otvorenu ranu u ustima) dok se liječite lijekom Imlygic i do 30 dana nakon Vaše posljednje doze.
English: Symptomatic herpetic infection due to possible reactivation of Imlygic should be considered.
Croatian: Treba imati na umu simptomatsku infekciju herpes virusom zbog moguće reaktivacije lijeka Imlygic.
English: • Side effects related to the immune system such as narrowing or blockage of blood vessels
Croatian: • Nuspojave povezane s imunološkim sustavom, poput suženja ili začepljenja krvnih žila
English: The modifications to talimogene laherparepvec from HSV-1 include deletion of ICP34.5 and ICP47.
Croatian: Modifikacije virusa HSV-1 u virus talimogene laherparepvec uključuju deleciju ICP34.5 i ICP47.
English: Patients may experience increase in size of existing lesion(s) or the appearance of a new lesion prior to achieving a response.
Croatian: U bolesnika može doći do povećanja postojeće/ih lezije/a ili pojave nove lezija prije postizanja odgovora.
English: Injury, poisoning and procedural complications Common
Croatian: Smanjenje tjelesne težine Ozljede, trovanja i proceduralne komplikacije Često
English: • Thawed Imlygic is stable when stored at temperatures of 2°C up to 25°C protected from light in its original vial, in a syringe, or in the original vial followed by a syringe.
Croatian: • Odmrznuti Imlygic je stabilan kada se čuva na temperaturi od 2°C do 25°C, zaštićen od svjetlosti u svojoj originalnoj bočici, u štrcaljki, ili u originalnoj bočici i zatim u štrcaljki.
English: Kaplan-Meier estimate of overall survival by randomised treatment arm for disease stage IIIB/IIIC/ stage IVM1a (exploratory subgroup analysis)
Croatian: Slika 5. Kaplan-Meierova procjena sveukupnog preživljenja po randomiziranoj terapijskoj skupini za stadij bolesti IIIB/IIIC/stadij bolesti IVM1a (eksploratorna analiza podskupina)
English: HSV-1 seronegative patients
Croatian: Bolesnici seronegativni na HSV-1
English: • After administration, change gloves prior to applying occlusive dressings to injected lesions.
Croatian: • Nakon primjene, promijenite rukavice prije nanošenja okluzivnog zavoja na lezije u koje je injiciran lijek.
English: This is a weakened form of herpes simplex virus type-1 (HSV-1), which is commonly called the cold sore virus.
Croatian: To je oslabljeni oblik virusa Herpes simplex tipa 1 (HSV-1), koji se često naziva groznica ili herpes.
English: No effects on embryo-foetal development have been observed in animal studies (see section 5.3).
Croatian: U ispitivanjima na životinjama nisu opaženi učinci na embrio-fetalni razvoj (vidjeti dio 5.3).
English: It is important for you to keep all your appointments to receive Imlygic.
Croatian: Važno je da održite sve svoje predviđene termine za primjenu lijeka Imlygic.
English: Advise patients to apply dressing as instructed by the healthcare professional and to replace the dressing if it falls off.
Croatian: Savjetujte bolesnike da primijene zavoj onako kako ih je uputio zdravstveni radnik te da zamijene zavoj ako otpadne.